Table 1

Patient characteristics

CharacteristicPN group
(n=38)
Non-PN group
(n=46)
P value
Age (years)54 (34–74)46 (27–73)0.0379
 ≥657 (18)2 (4)
 <6531 (82)44 (96)
Body Mass Index (kg/m2)0.3249
 >257 (18)5 (11)
 ≤2531 (82)41 (89)
Hormone receptor status0.9409
 ER+ and/or PgR+22 (58)27 (59)
 ER− and PgR−16 (42)19 (41)
HER2 status0.7123
 +13 (34)14 (30)
 –25 (66)32 (70)
Perioperative chemotherapy0.8649
 Neoadjuvant15 (39)20 (43)
 Adjuvant23 (61)26 (57)
Regimen0.3867
 AC f/b wPTX25 (66)26 (57)
 CEF f/b wPTX13 (34)20 (43)
  • Data are median (range) or number (%).

  • AC f/b wPTX, doxorubicin and cyclophosphamide followed by weekly paclitaxel; CEF f/b wPTX, cyclophosphamide, epirubicin and fluorouracil, followed by weekly paclitaxel; ER, oestrogen receptor; HER2, human epidermal growth factor receptor 2; PgR, progesterone receptor; PN, peripheral neuropathy.